Comments
Cut-throat competition is fast commoditising the erstwhile ‘highly specialised' pharmaceutical industry said market experts. There is huge global one-upmanship going on in the field of generics, they said.
Everyone wants to have his way on any drug that is going off-patent. The latest in the in list to feel the heat is Ranbaxy. “The big fish in the pharma industry worldwide are trying to eat away the smaller ones in order to grow,” said an industry expert.
“The frightening thing about this is the methods used are totally unethical in many cases,” he added. If companies are not able to buy out smaller players there have been instances of complaining to the FDA about players not following USFDA prescribed good manufacturing practices or even trying to buy out key personnel and ensure that the FDA approval of the smaller player is jeopardised.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.